美国AmProtein   
AmProtein由Amgen前蛋白质生产科学家Matthew Hui博士创建于2002年。
AmProtein发现了以DNA物理结构为基础的所有真核细胞通用的基因表达机制，无鼓泡的新型传氧机制，为现代生物技术做出了巨大贡献。

AmProtein将以DNA物理结构为基础的真核细胞通用基因表达机制此种机制定义为“GC-rich方法”。它将引领基因扩增后第二次生物革命，并带领世界商业化生物研究进入一个全新的领域。基于这种GC-rich方法，AmProtein发展出一套应用于哺乳动物细胞，鸡细胞，鱼细胞和可能的植物细胞基因表达载体并将其商业化，仅仅通过一些实验室规模的稳定的基因转染便可得到商业需求水平的蛋白质浓度。

基于无鼓泡式新型传氧机制，AmProtein成功开发出一次性生物工艺用塑料袋并已作商业化生产，可为高密度细胞提供高效溶氧的培养条件。在此基础上，AmProtein成功的衍生出了一套高密度细胞灌注培养系统。我们采用一次性的细胞贴壁纸片材料，并且使用悬浮培养系统作为溶氧生成器。

AmProtein将其高效表达系统应用于双体药物开发和快速生产，这将是生物技术的一次突破。AmProtein的载体系列和蛋白生产平台是快速发展重组蛋白、抗体、基因药物的理想选择。

AmProtein的表达载体和反应器系列均拥有世界专利，可根据客户需求提供相应许可。AmProtein拥有雄厚的科研力量，我们接受合同服务承接各大公司的项目及课题。

AmProtein将对全世界开放，寻求高瞻远瞩的合作者共同开发技术。目前我们在中国和美国的合作者都已开始分享AmProtein的技术带来的丰硕果实，我们在中国的合作者包括哈药集团，华北制药，西安新药中心，杭州安瑞普生物科技有限公司www.amprotein-china.com。在美国，AmProtein是加利福尼亚生物技术研究协会的成员，该技术研究协会由著名的前Amgen公司的科学家组成，更多信息请登陆：www.calbioresearch.com
AmProtein和华北制药集团新药研究中心、哈尔滨制药集团技术中心、哈药生物以及西安新药评价研究中心形成紧密的技术和生产联盟,以杭州为中心,已形成一个国际生物高技术平台,为中国奠定了生物工业基础。

AmProtein由六大功能区组成，其中五个研究方向是基于AmProtein在基因表达和传氧机制的重大世界性突破。我们的专利和概念已经扩展为横跨多个生物技术工程领域的一整条产业链。

AmProtein家族：

● 生物反应器&培养基

1、激流式悬浮&灌注生物反应器系统

2、模拟反应器系统

3、配套附件

● 表达系统

1、用于哺乳动物，鱼&鸡的pMH3-5 载体系列

2、来源于植物的载体系列正在研发中

● 医疗设备

“人工肺”心脏旁路溶氧生成器用于安全的长时间全血细胞培养&传氧

● 疫苗

1、关于哺乳动物，鱼和鸡疫苗生产高密度细胞培养工艺的突破

2、关于人类疫苗生产高密度细胞培养工艺的突破

● 治疗&合同服务

1、双体药物

2 、Hyper-G融合技术（取代Pegylation方法）

3、改制药与改制药仿制

● 市场

全球商业数据库

 
AmProtein is a biotech company founded in 2002 by Matthew Hui, MD, PhD, formerly a key protein production scientist at Amgen. AmProtein has developed a reputation as a biotechnology powerhouse that has revolutionized the modern biotechnology industry with the discovery of a DNA physical structure-based gene expression mechanism, common to all eukaryotic cells, and a novel, non-sparging-dependent O2 transfer method.

AmProtein has termed this mechanism the 'GC-rich method.' It has led to a second revolution after the gene amplification method, and has surely resulted in a new era in commercialized biologics research worldwide. Based on the GC-rich method, AmProtein has developed and commercialized a gene expression vector series for mammalian cells, chicken cells, fish cells, and possibly plant cells. By using the GC-rich method, one can reach commercial level protein titers after only a few laboratory-scale stable gene transfections.

Based on the above non-sparging O2 transfer method, we have successfully commercialized a single-use, plastic bag-based bioreactor series as an effective dissolved oxygen (DO) generator for high-density suspension cell culture.

In addition, AmProtein has successfully developed a high-density perfusion cell culture system by using a single-use, cell attachment paper-carrier material and our suspension culture system as a DO generator.

AmProtein has applied its expression system for the rapid production and subsequent development of our dual domain drug product candidates, the next IP frontier in biologics. AmProtein's vector series and protein production platform are ideal for the rapid development of recombinant protein, antibody, and generic drugs. Both AmProtein's revolutionary expression vector and superior bioreactor series are available for licensing. Also, AmProtein has the capability to support the projects of other companies through its Contract Research division.

AmProtein is open to fostering partnerships around the globe for the co-development of its technologies. Currently we enjoy fruitful collaborations is China and the United States. Our partners in China include Harbin Pharmaceutical Group Corporation, North China Pharmaceutical Corporation, Xian Drug Evaluation Center, and Hangzhou AmProtein Biotechnology Co., Ltd. www.amprotein-china.com. In America, AmProtein is a part of the California Biotechnology Research Consortium. The Consortium consists of companies started by well-known ex-Amgen scientists. See www.calbioresearch.com for more information.